Scarica l'app Stockscreener
87.16
0.22%
-0.19
Dopo l'orario di chiusura:
87.17
0.01
+0.01%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALC Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$87.35
Aprire:
$87.74
Volume 24 ore:
1.13M
Relative Volume:
0.71
Capitalizzazione di mercato:
$43.19B
Reddito:
$9.93B
Utile/perdita netta:
$1.12B
Rapporto P/E:
38.74
EPS:
2.25
Flusso di cassa netto:
$1.58B
1 W Prestazione:
-0.18%
1M Prestazione:
+2.06%
6M Prestazione:
-1.56%
1 anno Prestazione:
-3.17%
Intervallo 1D:
$87.10
$87.80
Intervallo di 1 settimana:
$85.52
$88.42
Portata 52W:
$80.48
$101.10
Alcon Inc Stock (ALC) Company Profile
Nome
Alcon Inc
Settore
Industria
Telefono
-
Indirizzo
-
Confronta ALC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALC
Alcon Inc
|
87.16 | 43.19B | 9.93B | 1.12B | 1.58B | 2.25 |
|
ISRG
Intuitive Surgical Inc
|
516.12 | 185.10B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
175.33 | 50.76B | 20.87B | 1.50B | 2.59B | 5.24 |
|
RMD
Resmed Inc
|
261.07 | 37.26B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
210.08 | 16.13B | 2.90B | 467.20M | 306.90M | 6.37 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-20 | Downgrade | Deutsche Bank | Buy → Hold |
| 2025-05-14 | Reiterato | BTIG Research | Buy |
| 2025-03-28 | Reiterato | Needham | Buy |
| 2025-03-25 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-01-24 | Reiterato | Needham | Buy |
| 2025-01-10 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2024-12-17 | Reiterato | Needham | Buy |
| 2024-11-12 | Reiterato | Needham | Buy |
| 2024-10-10 | Aggiornamento | Redburn Atlantic | Sell → Neutral |
| 2024-09-10 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-07-15 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2024-05-15 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-04-10 | Iniziato | Goldman | Buy |
| 2024-03-14 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2024-02-06 | Ripresa | KeyBanc Capital Markets | Overweight |
| 2024-01-23 | Iniziato | Bernstein | Outperform |
| 2023-12-18 | Downgrade | Redburn Atlantic | Neutral → Sell |
| 2023-12-12 | Iniziato | Stifel | Buy |
| 2023-12-04 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2023-08-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2023-03-01 | Aggiornamento | Societe Generale | Sell → Hold |
| 2022-12-22 | Iniziato | Mizuho | Buy |
| 2022-11-17 | Downgrade | Societe Generale | Hold → Sell |
| 2022-08-11 | Downgrade | Societe Generale | Buy → Hold |
| 2022-05-13 | Ripresa | Credit Suisse | Outperform |
| 2022-05-12 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2022-04-08 | Iniziato | Needham | Buy |
| 2022-03-11 | Iniziato | BofA Securities | Buy |
| 2022-01-18 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2022-01-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-01 | Iniziato | Oppenheimer | Perform |
| 2021-07-14 | Iniziato | Deutsche Bank | Buy |
| 2021-05-06 | Aggiornamento | Citigroup | Sell → Neutral |
| 2021-03-22 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-11-12 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-07-06 | Downgrade | Citigroup | Neutral → Sell |
| 2020-07-06 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2020-06-16 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-04-08 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | Aggiornamento | Argus | Hold → Buy |
| 2020-03-24 | Aggiornamento | Societe Generale | Sell → Hold |
| 2020-03-13 | Aggiornamento | UBS | Neutral → Buy |
| 2020-03-05 | Iniziato | Citigroup | Neutral |
| 2020-02-26 | Aggiornamento | Berenberg | Hold → Buy |
| 2020-01-08 | Iniziato | Argus | Hold |
| 2019-10-29 | Iniziato | Stephens | Equal-Weight |
| 2019-08-21 | Reiterato | BofA/Merrill | Neutral |
| 2019-06-24 | Iniziato | SVB Leerink | Mkt Perform |
| 2019-06-14 | Iniziato | BTIG Research | Neutral |
| 2019-05-10 | Iniziato | Robert W. Baird | Outperform |
| 2019-05-02 | Iniziato | Credit Suisse | Outperform |
Mostra tutto
Alcon Inc Borsa (ALC) Ultime notizie
What analysts say about Alcon Inc. stockExceptional market performance - Autocar Professional
Swiss Stocks Slip As Roche And Alcon Weigh On The Index - Finimize
RBC Sticks With Alcon As Equipment Sales Lead Growth - Finimize
Ophthalmic Implants Market: Focused Insights (2025-2030) Featuring Alcon, Carl Zeiss, Bausch + Lomb, Johnson & Johnson and 20 Other Industry Leaders - Yahoo Finance
Is Alcon Inc. a good long term investmentRapidly growing investment returns - PrintWeekIndia
What drives Alcon Inc. stock priceSuperior stock selection - jammulinksnews.com
Alcon Inc. Stock Analysis and ForecastRapid profit acceleration - Autocar Professional
September 19th Options Now Available For Alcon (ALC) - Nasdaq
Alcon Stock Gains Following UNITY VCS' Approval in Canada - MSN
Alcon’s Clareon PanOptix Pro IOL approved in Canada for cataract patients - Ophthalmology Times Europe
Stifel reiterates Buy rating on Alcon stock, maintains $100 price target - Investing.com Nigeria
Leadership watch: ViaLase, J&J, Alcon, and myze make executive additions - Eyes On Eyecare
Stifel reiterates Buy rating on Alcon stock, maintains $100 price target By Investing.com - Investing.com South Africa
Alcon Adds Noninvasive Treatment Solution, Acquires LumiThera | Business | Jul 2025 - Photonics Spectra
Alcon Names Julie M. Brewer to its Executive Leadership Team as SVP, President, Global Franchises - VisionMonday.com
Alcon sees the light with Lumithera buy for dry AMD - BioWorld MedTech
Alcon’s vitreoretinal-cataract system receives Health Canada approval By Investing.com - Investing.com South Africa
Alcon to acquire LumiThera for dry AMD treatment device - MSN
Alcon to purchase LumiThera - Eyes On Eyecare
Alcon's Unity VCS Gets Health Canada Approval - Nasdaq
Alcon snaps up LumiThera for light-based AMD treatment - Optics.org
Alcon Gets Health Canada Approval on Unity Vitreoretinal Cataract System - MarketScreener
Alcon’s vitreoretinal-cataract system receives Health Canada approval - Investing.com
Alcon : Names Julie M. Brewer to its Executive Leadership Team as SVP, President, Global Franchises - MarketScreener
Alcon’s Latest Breakthrough Surgical Technology, Unity VCS, receives Health Canada approval - Nasdaq
La dernière technologie chirurgicale révolutionnaire d’Alcon, Unity VCS, reçoit l’approbation de Santé Canada - New Castle News
Alcon Eyes Vitreoretinal Surgery Market Expansion in LumiThera Deal - MarketScreener
Alcon to acquire LumiThera and its dry AMD light therapy device - Investing.com Australia
Alcon Inc (ALC) Announces Approval of Clareon PanOptix Pro Intraocular Lens - MSN
Alcon's Bold Bet on Light Therapy: A New Dawn for Dry AMD and Retinal Dominance - AInvest
Alcon To Acquire LumiThera - citybiz
Alcon to acquire LumiThera and its photobiomodulation device for the treatment of dry AMD - Ophthalmology Times
Alcon To Acquire LumiThera And Its Photobiomodulation Device - Nasdaq
Alcon to acquire LumiThera and its dry AMD light therapy device By Investing.com - Investing.com South Africa
Alcon to Acquire LumiThera and Its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD) - Business Wire
Do Options Traders Know Something About Alcon Stock We Don't? - MSN
Is it Apt to Retain Alcon Stock in Your Portfolio for Now? - MSN
Alcon offers first look at TRYPTYR, debuts new innovations for contact lens ordering app - Eyes On Eyecare
Alcon Inc Azioni (ALC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.22%
1.97%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):